semaglutide oral cardiovascular indication 2025 news The FDA has approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, Wegovy HD, for weight loss and long-term weight maintenance in certain adult patients—in just 54 days from filing semaglutide oral cardiovascular indication 2025

With the help of celebrities and billionaires, versions of the drug have soared in demand this year as a temporary treatment for obesity

This is approximately one-tenth of the full therapeutic dose of 2.4 mg used in the STEP clinical trials for weight management

Studies point to oxidative stress and disturbances to the mitochondria, tiny organelles where the cells produce energy, as potential underlying causes of MF symptoms and dysfunction

This can be particularly beneficial for patients preparing for or recovering from procedures like SmartLipo, where maintaining a stable weight can optimize results and improve overall health outcomes